(NASDAQ:ZBIO), – Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 – – Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS) – – Secured development and commercialization rights for three autoimmune product candidates, including orelabrutinib, a BTK Inhibitor […]

Quick service restaurants with the strongest customer value propositions grew six times faster than most competitors dunnhumby, a global leader in customer data science, has named Buc-ee's as the top ranked U.S. quick service restaurant (QSR) in the Retailer Preference Index (RPI) QSR Edition. The RPI is a nationwide brand equity study that examines the

Brings Science-Backed, Transparency Driven Barrier Repair Worldwide Epicutis®, the science-driven skincare brand by biotech innovator Signum Biosciences, proudly announces its continued international expansion with the establishment of new offices in Sydney, Australia and Kyoto, Japan. This milestone marks a major step forward in Epicutis' mission to make clinical-grade, EWG-Verified skincare accessible to professionals and consumers

Achieves year-over-year gross margin expansion and $13.7 million increase in operating income – Updates full-year sales and adjusted EBITDA guidance – Pyxus International, Inc. (OTCID: PYYX) (“Pyxus,” the “Company,” “we,” or “our”), a global value-added agricultural company, today announced results for its second quarter ended September30, 2025. https://mma.prnewswire.com/media/1705892/Pyxus_Logo.jpg Pieter Sikkel, Pyxus' President and Chief Executive

Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswire November 12, 2025 – Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end – Presented new analysis of OLC data at American Society of Nephrology (ASN) which demonstrates that OLC significantly reduced pill burden

Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire November 12, 2025 – Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 – – Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS) – –

NEW YORK CITY, NY / ACCESS Newswire / November 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Fluor Corporation ("Fluor" or "the Company") (NYSE:FLR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants

Maxwell to operate as an independent business in the Clarios portfolio Clarios, a global leader in low-voltage energy storage solutions, today announced its acquisition of Maxwell Technologies, a manufacturer of supercapacitor cells and modules utilized in mobility, grid and onsite power applications, including for data centers. Terms of the deal were not disclosed. https://mma.prnewswire.com/media/2573556/Clarios_Logo.jpg This

NEW YORK CITY, NY / ACCESS Newswire / November 12, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against James Hardie Industries plc ("James Hardie" or the "Company") (NYSE:JHX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by

NEW YORK CITY, NY / ACCESS Newswire / November 12, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Fortinet, Inc. ("Fortinet" or the "Company") (NASDAQ:FTNT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged